Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sepsis | 5 | 2019 | 215 | 0.940 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2021 | 1 | 0.860 |
Why?
|
| Toll-Like Receptor 4 | 3 | 2013 | 318 | 0.820 |
Why?
|
| Sugar Phosphates | 2 | 2013 | 3 | 0.550 |
Why?
|
| Disaccharides | 2 | 2013 | 10 | 0.550 |
Why?
|
| Intensive Care Units | 6 | 2021 | 334 | 0.550 |
Why?
|
| Hospital Mortality | 4 | 2021 | 722 | 0.490 |
Why?
|
| Respiration, Artificial | 6 | 2021 | 218 | 0.460 |
Why?
|
| Respiratory Insufficiency | 3 | 2023 | 95 | 0.400 |
Why?
|
| Lipid A | 1 | 2010 | 69 | 0.380 |
Why?
|
| Integrins | 4 | 1997 | 100 | 0.360 |
Why?
|
| Bacterial Infections | 1 | 2010 | 120 | 0.350 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 623 | 0.330 |
Why?
|
| Mucoproteins | 2 | 1997 | 2 | 0.300 |
Why?
|
| Receptors, Lymphocyte Homing | 2 | 1997 | 15 | 0.300 |
Why?
|
| Double-Blind Method | 7 | 2023 | 549 | 0.300 |
Why?
|
| Immunoglobulins | 2 | 1997 | 76 | 0.290 |
Why?
|
| Critical Care | 4 | 2017 | 314 | 0.290 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2004 | 24 | 0.270 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2004 | 26 | 0.270 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 378 | 0.250 |
Why?
|
| Guideline Adherence | 2 | 2021 | 267 | 0.250 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2021 | 8 | 0.210 |
Why?
|
| Humans | 26 | 2023 | 49675 | 0.210 |
Why?
|
| Adult | 15 | 2023 | 13334 | 0.210 |
Why?
|
| Blood Gas Analysis | 2 | 2017 | 26 | 0.210 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 16 | 0.210 |
Why?
|
| Cannula | 1 | 2020 | 22 | 0.210 |
Why?
|
| Tidal Volume | 2 | 2019 | 19 | 0.200 |
Why?
|
| Male | 16 | 2021 | 23140 | 0.190 |
Why?
|
| Noninvasive Ventilation | 1 | 2020 | 66 | 0.190 |
Why?
|
| Female | 17 | 2021 | 26343 | 0.180 |
Why?
|
| Aged | 12 | 2021 | 10870 | 0.180 |
Why?
|
| Middle Aged | 13 | 2021 | 13451 | 0.180 |
Why?
|
| Patient Safety | 1 | 2020 | 189 | 0.170 |
Why?
|
| Acute Chest Syndrome | 1 | 2017 | 3 | 0.170 |
Why?
|
| Blood Substitutes | 1 | 2017 | 4 | 0.170 |
Why?
|
| Integrin beta Chains | 1 | 1997 | 2 | 0.170 |
Why?
|
| Multiple Organ Failure | 1 | 2017 | 35 | 0.160 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2017 | 39 | 0.160 |
Why?
|
| Protein C | 2 | 2008 | 27 | 0.160 |
Why?
|
| Hypoxia | 1 | 2017 | 73 | 0.160 |
Why?
|
| Hemoglobins | 1 | 2017 | 121 | 0.150 |
Why?
|
| Thiamine Deficiency | 1 | 2016 | 4 | 0.150 |
Why?
|
| Thiamine | 1 | 2016 | 17 | 0.150 |
Why?
|
| Lactic Acid | 1 | 2016 | 58 | 0.140 |
Why?
|
| Protein Structure, Tertiary | 1 | 1997 | 623 | 0.140 |
Why?
|
| APACHE | 3 | 2010 | 40 | 0.140 |
Why?
|
| Shock, Septic | 1 | 2016 | 65 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 680 | 0.140 |
Why?
|
| Shock | 1 | 2015 | 20 | 0.140 |
Why?
|
| Fluid Therapy | 1 | 2015 | 49 | 0.130 |
Why?
|
| Lymphocytes | 1 | 1994 | 170 | 0.120 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 1143 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2023 | 3888 | 0.120 |
Why?
|
| Infusions, Intravenous | 2 | 2010 | 153 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2019 | 2520 | 0.110 |
Why?
|
| United States | 5 | 2021 | 6234 | 0.110 |
Why?
|
| Gram-Positive Bacteria | 1 | 2011 | 33 | 0.110 |
Why?
|
| Gram-Negative Bacteria | 1 | 2011 | 49 | 0.110 |
Why?
|
| Phospholipids | 1 | 2011 | 72 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2021 | 2064 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 1936 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 787 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 38 | 0.100 |
Why?
|
| Renal Dialysis | 1 | 2011 | 167 | 0.100 |
Why?
|
| Antibodies, Neutralizing | 1 | 2011 | 180 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 250 | 0.090 |
Why?
|
| Critical Illness | 2 | 2010 | 254 | 0.090 |
Why?
|
| Choriocarcinoma | 1 | 2008 | 7 | 0.090 |
Why?
|
| Incidence | 2 | 2019 | 1122 | 0.090 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2008 | 12 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2010 | 473 | 0.090 |
Why?
|
| Uterine Neoplasms | 1 | 2008 | 31 | 0.090 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 58 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 729 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 3 | 1997 | 85 | 0.080 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2005 | 31 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2008 | 441 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2020 | 172 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2008 | 402 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 165 | 0.060 |
Why?
|
| Insulin | 1 | 2008 | 658 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2017 | 753 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2010 | 1574 | 0.060 |
Why?
|
| Pulmonary Circulation | 1 | 2003 | 22 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 224 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 66 | 0.060 |
Why?
|
| Hemodynamics | 1 | 2003 | 177 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 3 | 1997 | 414 | 0.060 |
Why?
|
| Neuromuscular Blockade | 1 | 2021 | 6 | 0.050 |
Why?
|
| Prone Position | 1 | 2021 | 16 | 0.050 |
Why?
|
| Positive-Pressure Respiration | 1 | 2021 | 27 | 0.050 |
Why?
|
| Early Medical Intervention | 1 | 2021 | 14 | 0.050 |
Why?
|
| Patient Positioning | 1 | 2021 | 30 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2021 | 43 | 0.050 |
Why?
|
| HIV Infections | 1 | 2008 | 898 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 173 | 0.050 |
Why?
|
| Heart | 1 | 2003 | 215 | 0.050 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 1997 | 6 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2011 | 2689 | 0.050 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 33 | 0.050 |
Why?
|
| Prognosis | 1 | 2004 | 1251 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2021 | 122 | 0.050 |
Why?
|
| Cell Adhesion | 3 | 1997 | 215 | 0.050 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 86 | 0.050 |
Why?
|
| HLA-DR Antigens | 1 | 2019 | 26 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 55 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 4220 | 0.050 |
Why?
|
| Lung | 1 | 2003 | 612 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1997 | 452 | 0.040 |
Why?
|
| Transfection | 2 | 1997 | 614 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2019 | 97 | 0.040 |
Why?
|
| Microvilli | 1 | 1997 | 4 | 0.040 |
Why?
|
| Methemoglobinemia | 1 | 2017 | 5 | 0.040 |
Why?
|
| Drug Evaluation | 1 | 2017 | 18 | 0.040 |
Why?
|
| Jehovah's Witnesses | 1 | 2017 | 14 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2020 | 4517 | 0.040 |
Why?
|
| Placebos | 1 | 2017 | 73 | 0.040 |
Why?
|
| Epitope Mapping | 1 | 1997 | 47 | 0.040 |
Why?
|
| North America | 1 | 2017 | 107 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 2017 | 54 | 0.040 |
Why?
|
| Pregnancy | 1 | 2004 | 2089 | 0.040 |
Why?
|
| Oximetry | 1 | 2017 | 35 | 0.040 |
Why?
|
| Cations | 1 | 1997 | 57 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 591 | 0.040 |
Why?
|
| Serine | 1 | 1997 | 82 | 0.040 |
Why?
|
| Leukocytes | 1 | 1997 | 106 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 429 | 0.040 |
Why?
|
| Acute Disease | 1 | 2019 | 604 | 0.040 |
Why?
|
| Erythrocyte Transfusion | 1 | 2017 | 76 | 0.040 |
Why?
|
| Cattle | 1 | 2017 | 293 | 0.040 |
Why?
|
| Survival Rate | 1 | 2019 | 656 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2021 | 471 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 1997 | 342 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 186 | 0.040 |
Why?
|
| Cross Infection | 1 | 2017 | 125 | 0.040 |
Why?
|
| Young Adult | 2 | 2017 | 3701 | 0.040 |
Why?
|
| Ligands | 1 | 1997 | 380 | 0.040 |
Why?
|
| Risk Factors | 1 | 2004 | 4248 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 1997 | 740 | 0.040 |
Why?
|
| Central Venous Pressure | 1 | 2015 | 12 | 0.030 |
Why?
|
| Furosemide | 1 | 2015 | 17 | 0.030 |
Why?
|
| Water-Electrolyte Balance | 1 | 2015 | 19 | 0.030 |
Why?
|
| Animals | 4 | 2017 | 17732 | 0.030 |
Why?
|
| Diuretics | 1 | 2015 | 51 | 0.030 |
Why?
|
| Pneumonia | 1 | 2017 | 233 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1002 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 1994 | 53 | 0.030 |
Why?
|
| Manganese | 1 | 1994 | 19 | 0.030 |
Why?
|
| Integrin beta1 | 1 | 1994 | 28 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 193 | 0.030 |
Why?
|
| Polymers | 1 | 2017 | 278 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 116 | 0.030 |
Why?
|
| Rats | 1 | 1997 | 1676 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 1997 | 1886 | 0.030 |
Why?
|
| Cell Line | 2 | 1997 | 1919 | 0.030 |
Why?
|
| Organ Dysfunction Scores | 1 | 2013 | 9 | 0.030 |
Why?
|
| Protein Binding | 1 | 1997 | 1475 | 0.030 |
Why?
|
| Mice | 2 | 1997 | 9096 | 0.030 |
Why?
|
| Hypertension | 1 | 2017 | 542 | 0.030 |
Why?
|
| Intestines | 1 | 1993 | 141 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 358 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1993 | 244 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 1993 | 314 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1993 | 568 | 0.020 |
Why?
|
| Respiratory Dead Space | 1 | 2008 | 2 | 0.020 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2008 | 5 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 13 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 70 | 0.020 |
Why?
|
| Viral Load | 1 | 2008 | 225 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2008 | 99 | 0.020 |
Why?
|
| Recurrence | 1 | 2008 | 496 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2008 | 275 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2008 | 154 | 0.020 |
Why?
|
| Drug Costs | 1 | 2005 | 51 | 0.020 |
Why?
|
| Software | 1 | 2008 | 327 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 1312 | 0.020 |
Why?
|
| Muscles | 1 | 1984 | 159 | 0.020 |
Why?
|
| Patient Selection | 1 | 2005 | 354 | 0.020 |
Why?
|
| Vascular Capacitance | 1 | 2003 | 2 | 0.020 |
Why?
|
| Cardiac Volume | 1 | 2003 | 7 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 641 | 0.020 |
Why?
|
| Ventricular Function | 1 | 2003 | 15 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 2003 | 36 | 0.020 |
Why?
|
| Ventricular Pressure | 1 | 2003 | 21 | 0.020 |
Why?
|
| Diastole | 1 | 2003 | 78 | 0.010 |
Why?
|
| HIV-1 | 1 | 2008 | 677 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 5324 | 0.010 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1997 | 11 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 1997 | 29 | 0.010 |
Why?
|
| Macrophage-1 Antigen | 1 | 1997 | 30 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1997 | 59 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1997 | 240 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1993 | 12 | 0.010 |
Why?
|
| Fibronectins | 1 | 1993 | 33 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1993 | 2017 | 0.010 |
Why?
|
| Rhodamines | 1 | 1984 | 20 | 0.000 |
Why?
|
| Glycerol | 1 | 1984 | 26 | 0.000 |
Why?
|
| Muscle Relaxation | 1 | 1984 | 23 | 0.000 |
Why?
|
| Rabbits | 1 | 1984 | 302 | 0.000 |
Why?
|
| Models, Biological | 1 | 1984 | 1096 | 0.000 |
Why?
|